Clarity Pharmaceuticals’ copper theranostics platform delivers superior prostate cancer imaging results

October 23, 2025 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Clarity Pharmaceuticals (ASX:CU6) has highlighted new clinical and commercial data supporting its proprietary copper-based theranostics platform, underscoring its potential to redefine imaging and therapy for prostate cancer. …

Subscribe now to continue reading.

Latest Video

New Zealand accelerates medicines reform with major regulatory changes
November 12, 2025 - Latest News
Government adds new first-line treatment to the PBS for deadly blood cancer
November 13, 2025
Sanofi building an AI-literate organisation through expectations, over experiments
November 14, 2025 - Latest News
Every Government agency to appoint a 'Chief AI Officer' under national plan
November 12, 2025 - Latest News
FDA moves to lift long-standing hormone therapy warnings in major shift for women’s health
November 12, 2025 - Latest News

Clarity Pharmaceuticals’ copper theranostics platform delivers superior prostate cancer imaging results

This is a preview of subscriber content

Latest Video

Most Read

New Zealand accelerates medicines reform with major regulatory changes

Government adds new first-line treatment to the PBS for deadly blood cancer

Sanofi building an AI-literate organisation through expectations, over experiments

Every Government agency to appoint a 'Chief AI Officer' under national plan

FDA moves to lift long-standing hormone therapy warnings in major shift for women’s health

New Stories

Arrotex launches new PBS-listed combination therapy as gap emerges in hypertension treatments

Sanofi building an AI-literate organisation through expectations, over experiments

Prospection says data access and leadership are critical to unlock AI’s potential in healthcare

The four 'H' words that can help drive the adoption of AI in health

Immutep posts encouraging Phase 2 results as 'Efti' spurs robust anti-tumour activity

PYC Therapeutics appoints Peter Coleman as new Chair as part of board renewal

New gene discoveries improve diagnosis of inherited heart disease

Sign In

Clarity Pharmaceuticals’ copper theranostics platform delivers superior prostate cancer imaging results

This is a preview of subscriber content

Latest Video

Most Read

New Zealand accelerates medicines reform with major regulatory changes

Government adds new first-line treatment to the PBS for deadly blood cancer

Sanofi building an AI-literate organisation through expectations, over experiments

Every Government agency to appoint a 'Chief AI Officer' under national plan

FDA moves to lift long-standing hormone therapy warnings in major shift for women’s health

Follow Us

New Stories

Arrotex launches new PBS-listed combination therapy as gap emerges in hypertension treatments

Sanofi building an AI-literate organisation through expectations, over experiments

Prospection says data access and leadership are critical to unlock AI’s potential in healthcare

The four 'H' words that can help drive the adoption of AI in health

Immutep posts encouraging Phase 2 results as 'Efti' spurs robust anti-tumour activity

PYC Therapeutics appoints Peter Coleman as new Chair as part of board renewal

New gene discoveries improve diagnosis of inherited heart disease